CA2176114A1 - Cytokines produites par des cellules tuteuses naturelles ou des lymphocytes t - Google Patents
Cytokines produites par des cellules tuteuses naturelles ou des lymphocytes tInfo
- Publication number
- CA2176114A1 CA2176114A1 CA002176114A CA2176114A CA2176114A1 CA 2176114 A1 CA2176114 A1 CA 2176114A1 CA 002176114 A CA002176114 A CA 002176114A CA 2176114 A CA2176114 A CA 2176114A CA 2176114 A1 CA2176114 A1 CA 2176114A1
- Authority
- CA
- Canada
- Prior art keywords
- cell
- cells
- ifn
- free preparation
- secretion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 70
- 102000004127 Cytokines Human genes 0.000 title claims abstract description 52
- 108090000695 Cytokines Proteins 0.000 title claims abstract description 52
- 210000000822 natural killer cell Anatomy 0.000 title claims description 26
- 210000004027 cell Anatomy 0.000 claims abstract description 124
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 89
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract description 89
- 230000028327 secretion Effects 0.000 claims abstract description 66
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 53
- 238000002360 preparation method Methods 0.000 claims abstract description 37
- 239000006228 supernatant Substances 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 8
- 230000000694 effects Effects 0.000 claims description 40
- 238000002965 ELISA Methods 0.000 claims description 19
- 102000004889 Interleukin-6 Human genes 0.000 claims description 18
- 108090001005 Interleukin-6 Proteins 0.000 claims description 18
- 230000004913 activation Effects 0.000 claims description 17
- 239000013543 active substance Substances 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 14
- 230000001939 inductive effect Effects 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 10
- 238000004113 cell culture Methods 0.000 claims description 10
- 238000006386 neutralization reaction Methods 0.000 claims description 9
- 102000000589 Interleukin-1 Human genes 0.000 claims description 8
- 108010002352 Interleukin-1 Proteins 0.000 claims description 8
- 102000004388 Interleukin-4 Human genes 0.000 claims description 8
- 108090000978 Interleukin-4 Proteins 0.000 claims description 8
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 8
- 230000006698 induction Effects 0.000 claims description 8
- 108010002386 Interleukin-3 Proteins 0.000 claims description 7
- 102000000646 Interleukin-3 Human genes 0.000 claims description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 6
- 102000003814 Interleukin-10 Human genes 0.000 claims description 6
- 108090000174 Interleukin-10 Proteins 0.000 claims description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 6
- 238000003306 harvesting Methods 0.000 claims description 6
- 230000037361 pathway Effects 0.000 claims description 6
- 230000019491 signal transduction Effects 0.000 claims description 6
- 229920002307 Dextran Polymers 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 102000035195 Peptidases Human genes 0.000 claims description 5
- 108091008874 T cell receptors Proteins 0.000 claims description 5
- 230000016396 cytokine production Effects 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 239000012228 culture supernatant Substances 0.000 claims description 4
- 239000002464 receptor antagonist Substances 0.000 claims description 4
- 229940044551 receptor antagonist Drugs 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 claims description 3
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 230000035755 proliferation Effects 0.000 claims description 3
- 229940076264 interleukin-3 Drugs 0.000 claims description 2
- 229940028885 interleukin-4 Drugs 0.000 claims description 2
- 229940100601 interleukin-6 Drugs 0.000 claims description 2
- 210000000628 antibody-producing cell Anatomy 0.000 claims 1
- 229940076144 interleukin-10 Drugs 0.000 claims 1
- 239000004576 sand Substances 0.000 claims 1
- 210000004457 myocytus nodalis Anatomy 0.000 description 23
- 230000000977 initiatory effect Effects 0.000 description 17
- 108010002616 Interleukin-5 Proteins 0.000 description 14
- 102000000743 Interleukin-5 Human genes 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 11
- 210000004989 spleen cell Anatomy 0.000 description 11
- 241001529936 Murinae Species 0.000 description 10
- 239000002609 medium Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000003248 secreting effect Effects 0.000 description 7
- 230000003393 splenic effect Effects 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 230000003844 B-cell-activation Effects 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 230000000284 resting effect Effects 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 3
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108700012920 TNF Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000011748 cell maturation Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 101100353161 Drosophila melanogaster prel gene Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 101150083678 IL2 gene Proteins 0.000 description 2
- 108010004729 Phycoerythrin Proteins 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 108010056508 proteinase R Proteins 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010001513 AIDS related complex Diseases 0.000 description 1
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 1
- 241001556567 Acanthamoeba polyphaga mimivirus Species 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- -1 IL-g Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- NHTGHBARYWONDQ-JTQLQIEISA-N L-α-methyl-Tyrosine Chemical compound OC(=O)[C@](N)(C)CC1=CC=C(O)C=C1 NHTGHBARYWONDQ-JTQLQIEISA-N 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241001400590 Richia Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000003229 cytophilic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- QYPNKSZPJQQLRK-UHFFFAOYSA-N tebufenozide Chemical compound C1=CC(CC)=CC=C1C(=O)NN(C(C)(C)C)C(=O)C1=CC(C)=CC(C)=C1 QYPNKSZPJQQLRK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5403—IL-3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/243—Colony Stimulating Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Préparations d'une cytokine, exempte de cellules, produite soit par des cellules tuteuses naturelles (NK) activées par de l'interleukine 2 (IL-2), soit par des lymphocytes T à CD4?+¿ activés par l'anticorps monoclonal anti-CD3. Ladite cytokine induit des sécrétions d'anticorps par les lymphocytes B activés. L'invention concerne également des procédés de production de surnageants exempts de cellules contenant ladtie cytokine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15051093A | 1993-11-10 | 1993-11-10 | |
| US150,510 | 1993-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2176114A1 true CA2176114A1 (fr) | 1995-05-18 |
Family
ID=22534880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002176114A Abandoned CA2176114A1 (fr) | 1993-11-10 | 1994-11-08 | Cytokines produites par des cellules tuteuses naturelles ou des lymphocytes t |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0726913A4 (fr) |
| JP (1) | JPH09505285A (fr) |
| AU (1) | AU1090895A (fr) |
| CA (1) | CA2176114A1 (fr) |
| WO (1) | WO1995013294A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9107906B1 (en) | 2014-10-28 | 2015-08-18 | Adma Biologics, Inc. | Compositions and methods for the treatment of immunodeficiency |
| US10259865B2 (en) | 2017-03-15 | 2019-04-16 | Adma Biologics, Inc. | Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection |
-
1994
- 1994-11-08 WO PCT/US1994/012835 patent/WO1995013294A1/fr not_active Ceased
- 1994-11-08 JP JP7513935A patent/JPH09505285A/ja active Pending
- 1994-11-08 EP EP95901809A patent/EP0726913A4/fr not_active Withdrawn
- 1994-11-08 CA CA002176114A patent/CA2176114A1/fr not_active Abandoned
- 1994-11-08 AU AU10908/95A patent/AU1090895A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1995013294A1 (fr) | 1995-05-18 |
| EP0726913A1 (fr) | 1996-08-21 |
| JPH09505285A (ja) | 1997-05-27 |
| AU1090895A (en) | 1995-05-29 |
| EP0726913A4 (fr) | 2000-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rousset et al. | Long-term cultured CD40-activated B lymphocytes differentiate into plasma cells in response to IL-10 but not IL-4 | |
| Blanca et al. | Human B cell activation by autologous NK cells is regulated by CD40-CD40 ligand interaction: role of memory B cells and CD5+ B cells | |
| Thyphronitis et al. | IgE secretion by Epstein-Barr virus-infected purified human B lymphocytes is stimulated by interleukin 4 and suppressed by interferon gamma. | |
| Xu-Amano et al. | Selective induction of Th2 cells in murine Peyer's patches by oral immunization | |
| Kishimoto | B-cell stimulatory factors (BSFs): molecular structure, biological function, and regulation of expression | |
| Mosmann et al. | Two types of mouse helper T-cell clone: implications for immune regulation | |
| Beagley et al. | Interleukins and IgA synthesis. Human and murine interleukin 6 induce high rate IgA secretion in IgA-committed B cells. | |
| Pene et al. | IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. | |
| Punnonen et al. | IL-13 induces proliferation, Ig isotype switching, and Ig synthesis by immature human fetal B cells. | |
| Snapper et al. | Natural killer cells induce activated murine B cells to secrete Ig. | |
| Banchereau et al. | Functional CD40 antigen on B cells, dendritic cells and fibroblasts | |
| Splawski et al. | Cytokine regulation of immunoglobulin secretion by neonatal lymphocytes. | |
| Hermann et al. | CD40 ligand‐positive CD8+ T cell clones allow B cell growth and differentiation | |
| Maddaly et al. | Receptors and signaling mechanisms for B-lymphocyte activation, proliferation and differentiation–insights from both in vivo and in vitro approaches | |
| Bass et al. | Evidence for mouse Th1-and Th2-like helper T cells in vivo. Selective reduction of Th1-like cells after total lymphoid irradiation. | |
| Defrance et al. | Human interleukin 4 down‐regulates the surface expression of CD5 on normal and leukemic B cells | |
| EP0505397B1 (fr) | Procede de fabrication de lignees de lymphocytes b humains avec dependance selon le facteur | |
| Smyth et al. | IL-7 regulation of cytotoxic lymphocytes: pore-forming protein gene expression, interferon-γ production, and cytotoxicity of human peripheral blood lymphocyte subsets | |
| Keegan et al. | Superinduction of the murine B cell Fc epsilon RII by T helper cell clones. Role of IL-4. | |
| Snapper et al. | IFN-γis a potent inducer of Ig secretion by sort-purified murine B cella activated through the mlg, but not the CD40, signaling pathway | |
| Quint et al. | Functional and phenotypic analysis of human T-cell clones which stimulate IgE production in vitro | |
| Jabara et al. | Engagement of CD14 on monocytes inhibits the synthesis of human Igs, including IgE. | |
| Pistoia et al. | Relationships between B cell cytokine production in secondary lymphoid follicles and apoptosis of germinal center B lymphocytes | |
| Eugui et al. | Antibodies against membrane interleukin 1 alpha activate accessory cells to stimulate proliferation of T lymphocytes. | |
| CA2176114A1 (fr) | Cytokines produites par des cellules tuteuses naturelles ou des lymphocytes t |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |